{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-025048","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.724169+00:00","generated_at":"2026-06-19T00:38:03.343868+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SELLAS Life Sciences prices $20M public offering of common stock and warrants","bullets":["7,220,217 shares and warrants at $2.77/unit; gross proceeds $20M.","Net proceeds ~$18.5M after underwriting discounts and offering expenses.","Warrants exercisable at $2.77/share, immediately exercisable, expire in 5 years.","Company reduces exercise price of 3,438,851 existing warrants to $3.62.","Offering expected to close on February 28, 2023, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-025048","json":"https://secwatch.observer/filing/0001104659-23-025048.json","markdown":"https://secwatch.observer/filing/0001104659-23-025048.md","text":"https://secwatch.observer/filing/0001104659-23-025048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923025048/0001104659-23-025048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923025048/tm237769d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:38:03.343868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"108f10b266e96d3506476d318704643a9957db07","claim":"SELLAS Life Sciences Group, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $18.5 million (effective 2023-02-23).","evidence_excerpt":"On February 23, 2023, SELLAS Life Sciences Group, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Cantor Fitzgerald & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to an underwritten public offering of 7,220,217 shares (the “ Underwritten Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and warrants (the “ Warrants ”, and together with the Underwritten Shares, the “ Securities ”) to purchase up to 7,220,217 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923025048/0001104659-23-025048-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"approximately $18.5 million"},{"label":"Effective","value":"2023-02-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}